Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy
Tóm tắt
The clinical efficacy of mizoribine (MZR; 4-carbamoyl-1-b-d-ribofuranosylimidazolium) in patients with lupus nephritis was investigated. Thirteen Japanese patients with biopsy-proved lupus nephritis were enrolled in this study. A change in global assessments score, total protein (TP) of serum, serum creatinine, creatinine clearance (Ccr), proteinuria, titers of serum anti-ds DNA antibody, C3, C4, and hemolytic complement activity (CH50) were examined. Following MZR treatment, the level of urinary protein decreased (P < 0.05), whereas the level of Ccr increased (P < 0.05). Moreover, the level of TP significantly increased from 5.5 g/dl to 6.3 g/dl (P < 0.01) and the level of C3 increased significantly (P < 0.01). However, there was no change in the levels of both C4 and CH50. The titer of anti-ds DNA antibody significantly decreased (P < 0.05). The dosage of prednisolone could be tapered from 24.8 mg to 14.9 mg daily during the period. The clinical effects associated with MZR concentration in the blood revealed that there was a significant correlation between the peak MZR blood concentration of more than 0.66 µg/ml and clinical improvement (P = 0.021). Our results suggest that an optimal MZR blood concentration was important for the treatment of lupus nephritis.
Tài liệu tham khảo
K Mizuno M Tsujino M Takada M Hayashi K Atsumi T Matsuda (1974) ArticleTitleStudies on bredinin. I. Isolation, characterization and biological properties J Antibiot (Tokyo) 27 775–84 Occurrence Handle1:CAS:528:DyaE2MXhtlOltLo%3D
H Ishikawa (1999) ArticleTitleMizolobine and mycophenolate mofetil Curr Med Chem 6 575–97 Occurrence Handle10390602 Occurrence Handle1:CAS:528:DyaK1MXks1Onsrc%3D
DA Gerber CA Bonham AW Thomson (1998) ArticleTitleImmunosuppressive agents: recent development in molecular action and chemical application Transplant Proc 1 89–90
M Suthanthiran RE Morris TB Strom (1996) ArticleTitleImmunosuppressants: cellular and molecular mechanisms of action Am J Kidney Dis 28 159–72 Occurrence Handle8768909 Occurrence Handle1:CAS:528:DyaK28XltFOltro%3D
SE Hughes SA Gruber (1996) ArticleTitleNew immunosuppressive drugs in organ transplantation J Clin Pharmacol 36 1081–92 Occurrence Handle9013363 Occurrence Handle1:CAS:528:DyaK2sXhtVWjsrg%3D
Y Kokado I Ishibashi H Jiang (1990) ArticleTitleLow dose cyclosporine, mizoribine and prednisolone in renal transplantation: a new triple therapy Clin Transplant 4 191–7
T Inoue R Kusaba I Takahashi H Sugumoto K Kuzuhara Y Yamada et al. (1981) ArticleTitleClinical trial of bredinine in renal transplantation Transplant Proc 13 315–8
Y Shiokawa R Akizuki R Yokohari H Hashimoto S Kashiwazaki H Kondo et al. (1991) ArticleTitleClinical evaluation of mizoribine on rheumatoid arthritis: a double-blind comparative study using lobenzariddisodium as a standard drug (in Japanese) Igakunoayumi 156 811–31
K Yoshioka Y Ohashi T Sakai H Ito N Yoshikawa H Nakamura et al. (2000) ArticleTitleA multicenter trial of mizoribine compared with placebo in children with frequency relapsing nephritic syndrome Kidney Int 58 317–24 Occurrence Handle10886577 Occurrence Handle10.1046/j.1523-1755.2000.00168.x Occurrence Handle1:CAS:528:DC%2BD3cXltVyjtbY%3D
K Kaneko R Nagaoka Y Ohtomo Y Yamashiro (1999) ArticleTitleMizoribine for childhood IgA nephropathy Nephron 83 376–7 Occurrence Handle10575308 Occurrence Handle10.1159/000045438 Occurrence Handle1:CAS:528:DyaK1MXnslKisrc%3D
Y Aihara T Miyamae S Ito S Kobayashi T Imagawa M Mori et al. (1999) ArticleTitleMizoribine as an effective combined maintenance therapy with prednisolone in childhood-onset systemic lupus erythematosus Pediatr Int 19 2–11
H Tanaka K Suzuki T Nakahata K Tsugawa E Ito S Wada (2003) ArticleTitleMizoribine oral pulse therapy for patients with disease flare of lupus nephritis Clin Nephrol 60 390–4 Occurrence Handle14690255 Occurrence Handle1:CAS:528:DC%2BD2cXpsFOm
T Fukunishi S Takahashi Y Hashinaka K Oota S Nagano K Takada et al. (1982) ArticleTitleBredinine concentration in blood and immunosuppressive effect (in Japanese) Ishyoku Jpn J Transplant 17 Suppl 750–2
K Sonda K Takahashi K Tanabe S Funchinose Y Hayasaka H Kawaguchi et al. (1996) ArticleTitleClinical pharmacokinetic study of mizoribine in renal transplantation patients Transplant Proc 28 3643–8 Occurrence Handle8962403 Occurrence Handle1:CAS:528:DyaK2sXisFKjsg%3D%3D
R Kusaba O Otubo T Inou M Yujino H Ishikawa (1982) ArticleTitleStudies on pharmacokinetics of bredinin (in Japanese with an English abstract) Isyoku 17 Suppl 585–93
S Koshikawa M Satou K Narita N Sakai T Shiiya T Koide et al. (1987) ArticleTitleClinical study of HE-69 (miziribine) on patients with incurable nephritic syndrome – a multicenter open study (in Japanese) Kidney Dial 23 971–80
H Warabi S Abe H Kondo Y Ishikawa S Sugawara K Shichikawa et al. (1991) ArticleTitleConsecutive administration of mizoribine in rheumatoid arthritis: pharmacokinetic study (in Japanese with an English abstract) Rheumatology 5 287–300
M Honma I Yoichi M Akizuki S Kashiwazaki H Kondo H Hashimoto et al. (1993) ArticleTitleLate phase 2 study of U67, 590A pulse therapy for lupus nephritis: dose finding study (in Japanese) Kisotorinsyo 27 5191–225
M Honma R Akizuki R Yokohari H Hashimoto S Kashiwazaki H Kondo et al. (1989) ArticleTitleClinical evaluation of mizoribine on lupus nephritis: multicenter single-blind comparative study with inactive placebo (in Japanese) Rinsyo-Igaku 5 795–824
H Tanaka K Suzuki T Nakahata T Sato E Ito (2003) ArticleTitleMizoribine oral pulse therapy for a patient with severe lupus nephritis Pediatr Int 45 488–90 Occurrence Handle12911493 Occurrence Handle10.1046/j.1442-200X.2003.01749.x
M Tokuda H Dobashi T Hiraishi H Mitsunaka J Takahashi M Hirohata (1998) ArticleTitleEffect of mizoribine pulse therapy on the disease activity of rheumatoid arthritis refractory to the treatment with methotrexate Rheumatology 20 525–6
H Tanaka K Tsugawa T Nakahata M Kudo S Onuma S Kimura et al. (2005) ArticleTitleMizoribine pulse therapy for a pediatric patient with steroid-resistant nephritic syndrome Tohoku J Exp Med 205 87–91 Occurrence Handle15635277 Occurrence Handle10.1620/tjem.205.87
Y Kawasaki J Suzuki A Takahashi M Isome R Nozawa H Suzuki (2005) ArticleTitleMizoribine oral pulse therapy for steroid-dependent nephritic syndrome Pediatr Nephrol 20 96–8 Occurrence Handle15503173 Occurrence Handle10.1007/s00467-004-1647-1
S Takei (2002) ArticleTitleMizoribine in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis Pediatr Int 44 205–9 Occurrence Handle11896888 Occurrence Handle10.1046/j.1328-8067.2002.01535.x Occurrence Handle1:CAS:528:DC%2BD38XjtlCisbo%3D